Atopic Dermatitis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：293頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Atopic Dermatitis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Atopic Dermatitis - Pipeline Review, H1 2014’, provides an overview of the Atopic Dermatitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Atopic Dermatitis - Pipeline Review, H1 2014’, provides an overview of the Atopic Dermatitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atopic Dermatitis Overview 11
Therapeutics Development 12
Pipeline Products for Atopic Dermatitis - Overview 12
Pipeline Products for Atopic Dermatitis - Comparative Analysis 13
Atopic Dermatitis - Therapeutics under Development by Companies 14
Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 20
Atopic Dermatitis - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Atopic Dermatitis - Products under Development by Companies 26
Atopic Dermatitis - Products under Investigation by Universities/Institutes 32
Atopic Dermatitis - Companies Involved in Therapeutics Development 33
Bristol-Myers Squibb Company 33
Johnson & Johnson 34
Kyowa Hakko Kirin Co., Ltd. 35
Daiichi Sankyo Company, Limited 36
Merck & Co., Inc. 37
Taisho Pharmaceutical Co., Ltd. 38
Takeda Pharmaceutical Company Limited 39
Novartis AG 40
Amorepacific Corporation 41
Chugai Pharmaceutical Co., Ltd. 42
Dr. Reddy's Laboratories Limited 43
Eisai Co., Ltd. 44
Galderma S.A. 45
LEO Pharma A/S 46
Mitsubishi Tanabe Pharma Corporation 47
Nippon Shinyaku Co., Ltd. 48
Pfizer Inc. 49
Sun Pharmaceutical Industries Limited 50
Sandoz Inc. 51
Celgene Corporation 52
Bayer AG 53
AlbireoPharma 54
NicOx S.A. 55
Nuvo Research Inc. 56
Regeneron Pharmaceuticals, Inc. 57
Array BioPharma Inc. 58
HanAll Biopharma Co., Ltd. 59
AnGes MG, Inc. 60
Provectus Biopharmaceuticals, Inc. 61
R-Tech Ueno, Ltd. 62
Paloma Pharmaceuticals, Inc. 63
Scynexis, Inc. 64
Upsher-Smith Laboratories, Inc. 65
Palau Pharma, S.A. 66
Foamix Ltd. 67
Respiratorius AB 68
Anacor Pharmaceuticals, Inc. 69
AnaptysBio, Inc. 70
IMMD Inc. 71
Circassia Ltd 72
Oxagen Limited 73
Therametrics holding AG 74
Melior Discovery, Inc. 75
Grupo Ferrer Internacional, S.A. 76
Welichem Biotech Inc. 77
ChemoCentryx, Inc. 78
Vitae Pharmaceuticals, Inc. 79
arGEN-X BV 80
SWITCH Biotech LLC 81
Pharis Biotec GmbH 82
Otsuka Holdings Co., Ltd. 83
LegoChem Biosciences, Inc 84
Fountain Biopharma Inc. 85
Oneness Biotech Co., Ltd. 86
Pergamum AB 87
VivaCell Biotechnology Espana S.L. 88
Brickell Biotech, Inc. 89
Neopharm Co., Ltd. 90
Laurantis Pharma Oy 91
Creabilis SA 92
sterna biologicals Gmbh & Co KG 93
Dermira Inc. 94
Dignity Sciences Ltd. 95
Thesan Pharmaceuticals, Inc. 96
ChironWells GmbH 97
Pharmedartis GmbH 98
Atopic Dermatitis - Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Target 100
Assessment by Mechanism of Action 104
Assessment by Route of Administration 109
Assessment by Molecule Type 112
Drug Profiles 115
bepotastine besylate - Drug Profile 115
dupilumab - Drug Profile 117
roflumilast - Drug Profile 119
tofacitinib - Drug Profile 122
CT-327 - Drug Profile 126
ustekinumab - Drug Profile 128
PH-10 - Drug Profile 130
DPK-060 - Drug Profile 132
cobamamide - Drug Profile 133
OC-459 - Drug Profile 134
LEO-29102 - Drug Profile 136
WBI-1001 - Drug Profile 137
ProtoCure Emulsion Cream - Drug Profile 139
AN-2898 - Drug Profile 141
ODC-9101 - Drug Profile 143
S-414114 - Drug Profile 144
mapracorat - Drug Profile 146
AN-2728 - Drug Profile 148
NS-141 - Drug Profile 150
DRM-02 - Drug Profile 151
E-6005 - Drug Profile 152
Product-0405 - Drug Profile 153
QAW-039 - Drug Profile 154
M-5200 - Drug Profile 156
QGE-031 - Drug Profile 157
CD-4802 - Drug Profile 159
DS-107-E - Drug Profile 160
SB-011 - Drug Profile 161
ASB-17061 - Drug Profile 162
CIM-331 - Drug Profile 163
KHK-4577 - Drug Profile 164
PDI-192 - Drug Profile 165
BPR-277 - Drug Profile 166
mometasone furoate - Drug Profile 167
BMS-981164 - Drug Profile 168
apremilast - Drug Profile 169
IMD-0354 - Drug Profile 171
S-414114 - Drug Profile 172
MK-8226 - Drug Profile 174
OPA-15406 - Drug Profile 175
DS-107-G - Drug Profile 176
LEO-39652 - Drug Profile 177
coagulation factor XIVa (human) - Drug Profile 178
Autologous Microbiome Transplant - Drug Profile 179
NCX-1047 - Drug Profile 180
SWT-01113 - Drug Profile 181
SWT-05141 - Drug Profile 182
PAR-2 Program - Drug Profile 183
RTU-1096 - Drug Profile 184
P-529 - Drug Profile 185
CIR-001 - Drug Profile 187
UR-65318 - Drug Profile 188
LEKTI-6 - Drug Profile 189
MLR-1130 - Drug Profile 190
A-3914 - Drug Profile 191
SIG-1311 - Drug Profile 192
RS-1154 - Drug Profile 193
RS-1269 - Drug Profile 194
Sun-0597 - Drug Profile 195
PAC-14028 - Drug Profile 197
CCX-6239 - Drug Profile 199
BBI-2111 - Drug Profile 200
ARRY-005 - Drug Profile 201
NPB-3 - Drug Profile 202
A-5425 - Drug Profile 203
betamethasone - Drug Profile 204
Q-2 - Drug Profile 205
CDE-001 - Drug Profile 206
ARN-077 - Drug Profile 207
WH-2 - Drug Profile 208
TKM-0150 - Drug Profile 209
ARGX-112 - Drug Profile 210
Small Molecules To Modulate Liver X Receptor For Dermatological Diseases - Drug Profile 211
AN-3485 - Drug Profile 212
DS-109 - Drug Profile 213
PMA-101R - Drug Profile 214
PMA-201 - Drug Profile 215
PMA-411R - Drug Profile 216
Small Molecule for Atopic Dermatitis - Drug Profile 217
FB-825 - Drug Profile 218
FIB-116 - Drug Profile 219
triamcinolone acetonide - Drug Profile 220
clobetasol propionate - Drug Profile 221
FP7 Project - Drug Profile 222
ANB-020 - Drug Profile 223
LCB-030110 - Drug Profile 224
Ipad Program - Drug Profile 225
WF-10 - Drug Profile 226
RESP-1200 - Drug Profile 228
PL-601 - Drug Profile 229
Cyclophilin Inhibitory Compounds - Drug Profile 230
HS-378 - Drug Profile 231
NPH-12 - Drug Profile 232
Synthetic Peptide to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 233
BB-2702 - Drug Profile 234
thymopentin - Drug Profile 235
DFD-02 - Drug Profile 236
Atopic Dermatitis - Recent Pipeline Updates 237
Atopic Dermatitis - Dormant Projects 273
Atopic Dermatitis - Discontinued Products 276
Atopic Dermatitis - Product Development Milestones 277
Featured News & Press Releases 277
Appendix 285
Methodology 285
Coverage 285
Secondary Research 285
Primary Research 285
Expert Panel Validation 285
Contact Us 286
Disclaimer 286
List of Tables
Number of Products under Development for Atopic Dermatitis, H1 2014 19
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 22
Number of Products under Development by Companies, H1 2014 (Contd..1) 23
Number of Products under Development by Companies, H1 2014 (Contd..2) 24
Number of Products under Development by Companies, H1 2014 (Contd..3) 25
Number of Products under Development by Companies, H1 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Development, H1 2014 31
Comparative Analysis by Unknown Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Development by Companies, H1 2014 (Contd..4) 37
Products under Development by Companies, H1 2014 (Contd..5) 38
Products under Investigation by Universities/Institutes, H1 2014 39
Atopic Dermatitis - Pipeline by Bristol-Myers Squibb Company, H1 2014 40
Atopic Dermatitis - Pipeline by Johnson & Johnson, H1 2014 41
Atopic Dermatitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 42
Atopic Dermatitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 43
Atopic Dermatitis - Pipeline by Merck & Co., Inc., H1 2014 44
Atopic Dermatitis - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 45
Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 46
Atopic Dermatitis - Pipeline by Novartis AG, H1 2014 47
Atopic Dermatitis - Pipeline by Amorepacific Corporation, H1 2014 48
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 49
Atopic Dermatitis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 50
Atopic Dermatitis - Pipeline by Eisai Co., Ltd., H1 2014 51
Atopic Dermatitis - Pipeline by Galderma S.A., H1 2014 52
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2014 53
Atopic Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 54
Atopic Dermatitis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 55
Atopic Dermatitis - Pipeline by Pfizer Inc., H1 2014 56
Atopic Dermatitis - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 57
Atopic Dermatitis - Pipeline by Sandoz Inc., H1 2014 58
Atopic Dermatitis - Pipeline by Celgene Corporation, H1 2014 59
Atopic Dermatitis - Pipeline by Bayer AG, H1 2014 60
Atopic Dermatitis - Pipeline by AlbireoPharma, H1 2014 61
Atopic Dermatitis - Pipeline by NicOx S.A., H1 2014 62
Atopic Dermatitis - Pipeline by Nuvo Research Inc., H1 2014 63
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 64
Atopic Dermatitis - Pipeline by Array BioPharma Inc., H1 2014 65
Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 66
Atopic Dermatitis - Pipeline by AnGes MG, Inc., H1 2014 67
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 68
Atopic Dermatitis - Pipeline by R-Tech Ueno, Ltd., H1 2014 69
Atopic Dermatitis - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 70
Atopic Dermatitis - Pipeline by Scynexis, Inc., H1 2014 71
Atopic Dermatitis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 72
Atopic Dermatitis - Pipeline by Palau Pharma, S.A., H1 2014 73
Atopic Dermatitis - Pipeline by Foamix Ltd., H1 2014 74
Atopic Dermatitis - Pipeline by Respiratorius AB, H1 2014 75
Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 76
Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H1 2014 77
Atopic Dermatitis - Pipeline by IMMD Inc., H1 2014 78
Atopic Dermatitis - Pipeline by Circassia Ltd, H1 2014 79
Atopic Dermatitis - Pipeline by Oxagen Limited, H1 2014 80
Atopic Dermatitis - Pipeline by Therametrics holding AG, H1 2014 81
Atopic Dermatitis - Pipeline by Melior Discovery, Inc., H1 2014 82
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 83
Atopic Dermatitis - Pipeline by Welichem Biotech Inc., H1 2014 84
Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H1 2014 85
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 86
Atopic Dermatitis - Pipeline by arGEN-X BV, H1 2014 87
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2014 88
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2014 89
Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 90
Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H1 2014 91
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H1 2014 92
Atopic Dermatitis - Pipeline by Oneness Biotech Co., Ltd., H1 2014 93
Atopic Dermatitis - Pipeline by Pergamum AB, H1 2014 94
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014 95
Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H1 2014 96
Atopic Dermatitis - Pipeline by Neopharm Co., Ltd., H1 2014 97
Atopic Dermatitis - Pipeline by Laurantis Pharma Oy, H1 2014 98
Atopic Dermatitis - Pipeline by Creabilis SA, H1 2014 99
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2014 100
Atopic Dermatitis - Pipeline by Dermira Inc., H1 2014 101
Atopic Dermatitis - Pipeline by Dignity Sciences Ltd., H1 2014 102
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H1 2014 103
Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2014 104
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2014 105
Assessment by Monotherapy Products, H1 2014 106
Number of Products by Stage and Target, H1 2014 109
Number of Products by Stage and Mechanism of Action, H1 2014 113
Number of Products by Stage and Route of Administration, H1 2014 118
Number of Products by Stage and Molecule Type, H1 2014 121
Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H1 2014 243
Atopic Dermatitis - Dormant Projects, H1 2014 279
Atopic Dermatitis - Dormant Projects (Contd..1), H1 2014 280
Atopic Dermatitis - Discontinued Products, H1 2014 282
List of Figures
Number of Products under Development for Atopic Dermatitis, H1 2014 19
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 21
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Products, H1 2014 31
Assessment by Monotherapy Products, H1 2014 106
Number of Products by Top 10 Target, H1 2014 107
Number of Products by Stage and Top 10 Target, H1 2014 108
Number of Products by Top 10 Mechanism of Action, H1 2014 111
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 112
Number of Products by Top 10 Route of Administration, H1 2014 116
Number of Products by Stage and Top 10 Route of Administration, H1 2014 117
Number of Products by Top 10 Molecule Type, H1 2014 119
Number of Products by Stage and Top 10 Molecule Type, H1 2014 120
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atopic Dermatitis Overview 11
Therapeutics Development 12
Pipeline Products for Atopic Dermatitis - Overview 12
Pipeline Products for Atopic Dermatitis - Comparative Analysis 13
Atopic Dermatitis - Therapeutics under Development by Companies 14
Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 20
Atopic Dermatitis - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Atopic Dermatitis - Products under Development by Companies 26
Atopic Dermatitis - Products under Investigation by Universities/Institutes 32
Atopic Dermatitis - Companies Involved in Therapeutics Development 33
Bristol-Myers Squibb Company 33
Johnson & Johnson 34
Kyowa Hakko Kirin Co., Ltd. 35
Daiichi Sankyo Company, Limited 36
Merck & Co., Inc. 37
Taisho Pharmaceutical Co., Ltd. 38
Takeda Pharmaceutical Company Limited 39
Novartis AG 40
Amorepacific Corporation 41
Chugai Pharmaceutical Co., Ltd. 42
Dr. Reddy's Laboratories Limited 43
Eisai Co., Ltd. 44
Galderma S.A. 45
LEO Pharma A/S 46
Mitsubishi Tanabe Pharma Corporation 47
Nippon Shinyaku Co., Ltd. 48
Pfizer Inc. 49
Sun Pharmaceutical Industries Limited 50
Sandoz Inc. 51
Celgene Corporation 52
Bayer AG 53
AlbireoPharma 54
NicOx S.A. 55
Nuvo Research Inc. 56
Regeneron Pharmaceuticals, Inc. 57
Array BioPharma Inc. 58
HanAll Biopharma Co., Ltd. 59
AnGes MG, Inc. 60
Provectus Biopharmaceuticals, Inc. 61
R-Tech Ueno, Ltd. 62
Paloma Pharmaceuticals, Inc. 63
Scynexis, Inc. 64
Upsher-Smith Laboratories, Inc. 65
Palau Pharma, S.A. 66
Foamix Ltd. 67
Respiratorius AB 68
Anacor Pharmaceuticals, Inc. 69
AnaptysBio, Inc. 70
IMMD Inc. 71
Circassia Ltd 72
Oxagen Limited 73
Therametrics holding AG 74
Melior Discovery, Inc. 75
Grupo Ferrer Internacional, S.A. 76
Welichem Biotech Inc. 77
ChemoCentryx, Inc. 78
Vitae Pharmaceuticals, Inc. 79
arGEN-X BV 80
SWITCH Biotech LLC 81
Pharis Biotec GmbH 82
Otsuka Holdings Co., Ltd. 83
LegoChem Biosciences, Inc 84
Fountain Biopharma Inc. 85
Oneness Biotech Co., Ltd. 86
Pergamum AB 87
VivaCell Biotechnology Espana S.L. 88
Brickell Biotech, Inc. 89
Neopharm Co., Ltd. 90
Laurantis Pharma Oy 91
Creabilis SA 92
sterna biologicals Gmbh & Co KG 93
Dermira Inc. 94
Dignity Sciences Ltd. 95
Thesan Pharmaceuticals, Inc. 96
ChironWells GmbH 97
Pharmedartis GmbH 98
Atopic Dermatitis - Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Target 100
Assessment by Mechanism of Action 104
Assessment by Route of Administration 109
Assessment by Molecule Type 112
Drug Profiles 115
bepotastine besylate - Drug Profile 115
dupilumab - Drug Profile 117
roflumilast - Drug Profile 119
tofacitinib - Drug Profile 122
CT-327 - Drug Profile 126
ustekinumab - Drug Profile 128
PH-10 - Drug Profile 130
DPK-060 - Drug Profile 132
cobamamide - Drug Profile 133
OC-459 - Drug Profile 134
LEO-29102 - Drug Profile 136
WBI-1001 - Drug Profile 137
ProtoCure Emulsion Cream - Drug Profile 139
AN-2898 - Drug Profile 141
ODC-9101 - Drug Profile 143
S-414114 - Drug Profile 144
mapracorat - Drug Profile 146
AN-2728 - Drug Profile 148
NS-141 - Drug Profile 150
DRM-02 - Drug Profile 151
E-6005 - Drug Profile 152
Product-0405 - Drug Profile 153
QAW-039 - Drug Profile 154
M-5200 - Drug Profile 156
QGE-031 - Drug Profile 157
CD-4802 - Drug Profile 159
DS-107-E - Drug Profile 160
SB-011 - Drug Profile 161
ASB-17061 - Drug Profile 162
CIM-331 - Drug Profile 163
KHK-4577 - Drug Profile 164
PDI-192 - Drug Profile 165
BPR-277 - Drug Profile 166
mometasone furoate - Drug Profile 167
BMS-981164 - Drug Profile 168
apremilast - Drug Profile 169
IMD-0354 - Drug Profile 171
S-414114 - Drug Profile 172
MK-8226 - Drug Profile 174
OPA-15406 - Drug Profile 175
DS-107-G - Drug Profile 176
LEO-39652 - Drug Profile 177
coagulation factor XIVa (human) - Drug Profile 178
Autologous Microbiome Transplant - Drug Profile 179
NCX-1047 - Drug Profile 180
SWT-01113 - Drug Profile 181
SWT-05141 - Drug Profile 182
PAR-2 Program - Drug Profile 183
RTU-1096 - Drug Profile 184
P-529 - Drug Profile 185
CIR-001 - Drug Profile 187
UR-65318 - Drug Profile 188
LEKTI-6 - Drug Profile 189
MLR-1130 - Drug Profile 190
A-3914 - Drug Profile 191
SIG-1311 - Drug Profile 192
RS-1154 - Drug Profile 193
RS-1269 - Drug Profile 194
Sun-0597 - Drug Profile 195
PAC-14028 - Drug Profile 197
CCX-6239 - Drug Profile 199
BBI-2111 - Drug Profile 200
ARRY-005 - Drug Profile 201
NPB-3 - Drug Profile 202
A-5425 - Drug Profile 203
betamethasone - Drug Profile 204
Q-2 - Drug Profile 205
CDE-001 - Drug Profile 206
ARN-077 - Drug Profile 207
WH-2 - Drug Profile 208
TKM-0150 - Drug Profile 209
ARGX-112 - Drug Profile 210
Small Molecules To Modulate Liver X Receptor For Dermatological Diseases - Drug Profile 211
AN-3485 - Drug Profile 212
DS-109 - Drug Profile 213
PMA-101R - Drug Profile 214
PMA-201 - Drug Profile 215
PMA-411R - Drug Profile 216
Small Molecule for Atopic Dermatitis - Drug Profile 217
FB-825 - Drug Profile 218
FIB-116 - Drug Profile 219
triamcinolone acetonide - Drug Profile 220
clobetasol propionate - Drug Profile 221
FP7 Project - Drug Profile 222
ANB-020 - Drug Profile 223
LCB-030110 - Drug Profile 224
Ipad Program - Drug Profile 225
WF-10 - Drug Profile 226
RESP-1200 - Drug Profile 228
PL-601 - Drug Profile 229
Cyclophilin Inhibitory Compounds - Drug Profile 230
HS-378 - Drug Profile 231
NPH-12 - Drug Profile 232
Synthetic Peptide to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 233
BB-2702 - Drug Profile 234
thymopentin - Drug Profile 235
DFD-02 - Drug Profile 236
Atopic Dermatitis - Recent Pipeline Updates 237
Atopic Dermatitis - Dormant Projects 273
Atopic Dermatitis - Discontinued Products 276
Atopic Dermatitis - Product Development Milestones 277
Featured News & Press Releases 277
Appendix 285
Methodology 285
Coverage 285
Secondary Research 285
Primary Research 285
Expert Panel Validation 285
Contact Us 286
Disclaimer 286
List of Tables
Number of Products under Development for Atopic Dermatitis, H1 2014 19
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 22
Number of Products under Development by Companies, H1 2014 (Contd..1) 23
Number of Products under Development by Companies, H1 2014 (Contd..2) 24
Number of Products under Development by Companies, H1 2014 (Contd..3) 25
Number of Products under Development by Companies, H1 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Development, H1 2014 31
Comparative Analysis by Unknown Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Development by Companies, H1 2014 (Contd..4) 37
Products under Development by Companies, H1 2014 (Contd..5) 38
Products under Investigation by Universities/Institutes, H1 2014 39
Atopic Dermatitis - Pipeline by Bristol-Myers Squibb Company, H1 2014 40
Atopic Dermatitis - Pipeline by Johnson & Johnson, H1 2014 41
Atopic Dermatitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 42
Atopic Dermatitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 43
Atopic Dermatitis - Pipeline by Merck & Co., Inc., H1 2014 44
Atopic Dermatitis - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 45
Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 46
Atopic Dermatitis - Pipeline by Novartis AG, H1 2014 47
Atopic Dermatitis - Pipeline by Amorepacific Corporation, H1 2014 48
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 49
Atopic Dermatitis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 50
Atopic Dermatitis - Pipeline by Eisai Co., Ltd., H1 2014 51
Atopic Dermatitis - Pipeline by Galderma S.A., H1 2014 52
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2014 53
Atopic Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 54
Atopic Dermatitis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 55
Atopic Dermatitis - Pipeline by Pfizer Inc., H1 2014 56
Atopic Dermatitis - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 57
Atopic Dermatitis - Pipeline by Sandoz Inc., H1 2014 58
Atopic Dermatitis - Pipeline by Celgene Corporation, H1 2014 59
Atopic Dermatitis - Pipeline by Bayer AG, H1 2014 60
Atopic Dermatitis - Pipeline by AlbireoPharma, H1 2014 61
Atopic Dermatitis - Pipeline by NicOx S.A., H1 2014 62
Atopic Dermatitis - Pipeline by Nuvo Research Inc., H1 2014 63
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 64
Atopic Dermatitis - Pipeline by Array BioPharma Inc., H1 2014 65
Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 66
Atopic Dermatitis - Pipeline by AnGes MG, Inc., H1 2014 67
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 68
Atopic Dermatitis - Pipeline by R-Tech Ueno, Ltd., H1 2014 69
Atopic Dermatitis - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 70
Atopic Dermatitis - Pipeline by Scynexis, Inc., H1 2014 71
Atopic Dermatitis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 72
Atopic Dermatitis - Pipeline by Palau Pharma, S.A., H1 2014 73
Atopic Dermatitis - Pipeline by Foamix Ltd., H1 2014 74
Atopic Dermatitis - Pipeline by Respiratorius AB, H1 2014 75
Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 76
Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H1 2014 77
Atopic Dermatitis - Pipeline by IMMD Inc., H1 2014 78
Atopic Dermatitis - Pipeline by Circassia Ltd, H1 2014 79
Atopic Dermatitis - Pipeline by Oxagen Limited, H1 2014 80
Atopic Dermatitis - Pipeline by Therametrics holding AG, H1 2014 81
Atopic Dermatitis - Pipeline by Melior Discovery, Inc., H1 2014 82
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 83
Atopic Dermatitis - Pipeline by Welichem Biotech Inc., H1 2014 84
Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H1 2014 85
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 86
Atopic Dermatitis - Pipeline by arGEN-X BV, H1 2014 87
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2014 88
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2014 89
Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 90
Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H1 2014 91
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H1 2014 92
Atopic Dermatitis - Pipeline by Oneness Biotech Co., Ltd., H1 2014 93
Atopic Dermatitis - Pipeline by Pergamum AB, H1 2014 94
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014 95
Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H1 2014 96
Atopic Dermatitis - Pipeline by Neopharm Co., Ltd., H1 2014 97
Atopic Dermatitis - Pipeline by Laurantis Pharma Oy, H1 2014 98
Atopic Dermatitis - Pipeline by Creabilis SA, H1 2014 99
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2014 100
Atopic Dermatitis - Pipeline by Dermira Inc., H1 2014 101
Atopic Dermatitis - Pipeline by Dignity Sciences Ltd., H1 2014 102
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H1 2014 103
Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2014 104
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2014 105
Assessment by Monotherapy Products, H1 2014 106
Number of Products by Stage and Target, H1 2014 109
Number of Products by Stage and Mechanism of Action, H1 2014 113
Number of Products by Stage and Route of Administration, H1 2014 118
Number of Products by Stage and Molecule Type, H1 2014 121
Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H1 2014 243
Atopic Dermatitis - Dormant Projects, H1 2014 279
Atopic Dermatitis - Dormant Projects (Contd..1), H1 2014 280
Atopic Dermatitis - Discontinued Products, H1 2014 282
List of Figures
Number of Products under Development for Atopic Dermatitis, H1 2014 19
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 21
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Products, H1 2014 31
Assessment by Monotherapy Products, H1 2014 106
Number of Products by Top 10 Target, H1 2014 107
Number of Products by Stage and Top 10 Target, H1 2014 108
Number of Products by Top 10 Mechanism of Action, H1 2014 111
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 112
Number of Products by Top 10 Route of Administration, H1 2014 116
Number of Products by Stage and Top 10 Route of Administration, H1 2014 117
Number of Products by Top 10 Molecule Type, H1 2014 119
Number of Products by Stage and Top 10 Molecule Type, H1 2014 120
